Body mass index reduction (BMI reduction) (BMI reduction)

Body mass index (BMI) reduction is a primary clinical endpoint and therapeutic objective in the management of obesity and its comorbidities, rather than a specific molecular target like a protein or receptor [1, 10]. It is defined as a decrease in the calculated ratio of a person’s weight to their height squared, which serves as a widely accepted proxy for total body fatness [10, 11]. Unlike a singular biological molecule, BMI reduction represents a complex physiological outcome resulting from changes in energy balance regulated by the interaction of genetic, environmental, and behavioral factors [5, 8]. Modern pharmacotherapy achieves BMI reduction by modulating specific molecular targets within the central nervous system and gastrointestinal tract—most notably the Glucagon-like peptide-1 receptor (GLP-1R), Gastric inhibitory polypeptide receptor (GIPR), and Melanocortin-4 receptor (MC4R) [3, 5, 12]. Drugs like tirzepatide and semaglutide promote significant BMI reduction by enhancing satiety and regulating insulin secretion, while others may target metabolic efficiency or fat absorption [4, 11, 13]. As a global measure of adiposity, BMI reduction is the standard metric used in clinical trials to assess the efficacy of anti-obesity medications [6, 14].

Other names

Weight lossBody weight reductionDecrease in BMIAdiposity reduction

BMI reduction is achieved by modulating molecular pathways that govern hunger, satiety, and metabolic rate, specifically by activating receptors such as GLP-1R and MC4R or by inhibiting lipid absorption via gastric and pancreatic lipases.